Theravance Biopharma (TBPH)
(Delayed Data from NSDQ)
$7.66 USD
-0.02 (-0.26%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $7.66 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth C Momentum F VGM
Price, Consensus and EPS Surprise
TBPH 7.66 -0.02(-0.26%)
Will TBPH be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for TBPH based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for TBPH
Theravance (TBPH) Q2 Loss Wider Than Expected, Revenues Rise Y/Y
Theravance Biopharma (TBPH) Reports Q2 Loss, Lags Revenue Estimates
TBPH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Best Momentum Stocks to Buy for July 15th
New Strong Buy Stocks for July 15th
AstraZeneca's (AZN) Imfinzi Meets Study Goal in Bladder Cancer
Other News for TBPH
Small Cap Stocks: TBPH Stock Isn’t Ideal for Short Term Investors
Cracking The Code: Understanding Analyst Reviews For Theravance Biopharma
Theravance Biopharma (TBPH) Receives a Hold from Evercore ISI
Hold Rating on Theravance Biopharma Amidst Revised Revenue Projections and Pipeline Delays
Theravance Biopharma just downgraded at Leerink, here's why